Keyphrases
Older Adults
100%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
100%
Pooled Safety Analysis
100%
Tisagenlecleucel
100%
Cytokine Release Syndrome
50%
Pooled Analysis
33%
Safety Profile
33%
Neurological Events
33%
Adverse Events
16%
Corticosteroids
16%
Clinical Trials
16%
Long Follow-up
16%
Relapsed or Refractory
16%
Phase II Trial
16%
Tocilizumab
16%
Chimeric Antigen Receptor T-cell Therapy
16%
Cytopenia
16%
Adverse Event Management
16%
Adverse Events of Interest
16%
Anti-CD19 chimeric Antigen Receptor T Cells
16%
Tumor Lysis Syndrome
16%
Management Guidance
16%
Nursing and Health Professions
Adverse Event
100%
Acute Lymphoblastic Leukemia
100%
Cytokine Release Syndrome
100%
Infection
33%
Tocilizumab
33%
Cytopenia
33%
Chimeric Antigen Receptor T-Cell Immunotherapy
33%
Tumor Lysis Syndrome
33%
Efficacy
33%
Immunology and Microbiology
B Cell
100%
Cytokine Release Syndrome
100%
CD19
33%
Tumor Cell Destruction
33%
Tocilizumab
33%
Chimeric Antigen Receptor T-Cell Therapy
33%
Infection
33%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Cytokine Release Syndrome
100%
Clinical Trial
33%
T Cell
33%
CD19
33%
Chimeric Antigen Receptor
33%
Tumor Cell Destruction
33%